SCHEMBL9893692

SCHEMBL9893692

Cc1ccc(-c2nc(C(=O)O)c(-c3ccc(F)c(Cl)c3)n2-c2cc(Cl)ccc2C)cc1C

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 7/20 0.68
MARS1 P56192 1/20 0.41
MAPT P10636 1/20 0.40
KMO O15229 2/20 0.40
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
HTT P42858 1/20 0.37
CCR2 P41597 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
RPA1 P27694 1/20 0.36
MYC P01106 1/20 0.36
NOTUM Q6P988 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437173 0.93 MDM2 (0.69) MDM2MAPTKMOGABRA2GABRB2
SCHEMBL27879166 0.93 MDM2 (0.69) MDM2MARS1MAPTKMOGABRA2
SCHEMBL9894045 0.92 MDM2 (0.82) MDM2MARS1KMOGABRA2GABRB2
SCHEMBL9894206 0.91 MDM2 (0.83) MDM2MARS1MAPTKMOTP53
SCHEMBL1437137 0.88 MDM2 (0.87) MDM2MAPTHTTCCR2TP53
SCHEMBL1437178 0.88 MDM2 (0.53) MDM2MAPTGABRA2GABRB2
SCHEMBL27879169 0.88 MDM2 (0.69) MDM2MARS1MAPTKMOTP53
SCHEMBL9893866 0.87 MDM2 (0.62) MDM2MARS1MAPTKMOGABRA2
SCHEMBL27862924 0.86 MDM2 (0.66) MDM2MARS1MAPTKMOGABRA2
SCHEMBL1443393 0.85 MDM2 (0.66) MDM2KMOGABRA2GABRB2CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574785-A Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators NOVARTIS AG 2012-07-11 CN disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885MARS1 418/4885MAPT 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.